Abstract
Flaviviruses are vector-borne positive sense RNA viruses with enormous potential to cause a spectrum of severe diseases in naïve populations and long-term public health impact. Several of these Flavivirus es can co-circulate; recently, Zika virus (ZIKV) is becoming increasingly prevalent in Dengue virus (DENV) endemic regions. Pre-existing immunity to one virus can modulate the response to a heterologous virus; however, the serological cross-reaction between these emerging viruses in DENV endemic region are poorly understood. In this study, we estimated the seropositivity rates of nine different Flavivirus es among residents of Manaus city in Brazil. Next, we assessed antibody cross-reactivity of DENV-positive individuals with ZIKV using hemagglutination inhibition assay (HIA), purified envelope proteins in an ELISA, and live virus neutralization test. 74.52% of participants were IgG positive (310/416) as estimated by lateral flow tests. Overall, 93.7% of participants were seropositive (419/447) for at least one DENV serotype and the DENV seropositivity ranged between 84.8% and 91.0% as determined by HIA. DENV positive individuals with high antibody titers in HIA or envelope protein domain III (EDIII)-ELISA reacted strongly with ZIKV, whereas individuals with low anti-DENV antibody titers reacted poorly towards ZIKV. Live virus neutralization test with ZIKV confirmed that dengue serogroup and ZIKV-spondweni serogroup are distant and DENV-positive individuals do not cross-neutralize ZIKV efficiently. Taken together, we observed a high prevalence of DENV in the Manaus-Amazon region and a varying degree of serological reactivity against emerging viruses. Ecological and epidemiological conditions in Manaus makes its population susceptible for further arbovirus outbreaks; hence functional vector control program and febrile-syndrome surveillance are essential to identify unforeseen epidemiological threats.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
PL was supported by grants from Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM), Department of Science and Technology, Ministry of Health (DECIT/SCTIE/MS). PFCV is fellow of the CNPq and supported by grants. JLPM was financially supported by the Sao Paulo Research Foundation (FAPESP 2016/00194-8 and 2020/04558-0), National Council for Scientific and Technological Development (CNPq 305628/2020-8) and Fundo de Apoio ao Ensino, Pesquisa e Extensao (FAEPEX 2266/20 and 0002/20). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of this manuscript. We thank FAPEAM POSGRAD for support. BBS and FCJM received scholarship from CAPES, PLP received scholarship from CAPES from FAPESP and DATT received scholarship from CNPq.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Ethics Committee of the Universidade Federal do Amazonas (UFAM) gave ethical approval for this work, with approval number CAAE 96171218.7.0000.5020, in accordance with the Brazilian law, which complied with the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: PL was supported by grants from Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM), Department of Science and Technology, Ministry of Health (DECIT/SCTIE/MS). PFCV is fellow of the CNPq and supported by grants. JLPM was financially supported by the São Paulo Research Foundation (FAPESP 2016/00194-8 and 2020/04558-0), National Council for Scientific and Technological Development (CNPq 305628/2020-8) and Fundo de Apoio ao Ensino, Pesquisa e Extensão (FAEPEX 2266/20 and 0002/20). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of this manuscript. We thank FAPEAM POSGRAD for support. BBS and FCJM received scholarship from CAPES, PLP received scholarship from CAPES from FAPESP and DATT received scholarship from CNPq.
Data Availability
All data produced in the present work are contained in the manuscript
